JNJ-55920839

· Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JNJ-55920839, covering 2025-02-03 to 2025-02-03. Get the full timeline:

Most recent: Clinical Trial Update: A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus [Phase 1]

See pricing